FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2145758314> ?p ?o ?g. }

• W2145758314 endingPage "11" @default.
• W2145758314 startingPage "3303" @default.
• W2145758314 abstract "Our preclinical studies have shown that acidic and basic fibroblastic growth factors confer broad spectrum chemoresistance and that low concentrations (10-50 microM) of suramin, a nonspecific fibroblastic growth factor inhibitor, enhance the antitumor activity of paclitaxel in vivo. The present Phase I study evaluated low-dose suramin in combination with paclitaxel/carboplatin in advanced non-small cell lung cancer patients.Patients received suramin followed by paclitaxel (175-200 mg/m(2)) and carboplatin area under the concentration-time curve of 6 mg/ml/min, every 3 weeks. The initial suramin dose for the first cycle was 240 mg/m(2), and the doses for subsequent cycles were calculated based on the 72-h pretreatment plasma concentrations. The recommended suramin dose would yield plasma concentrations of 10-20 microM at 48 h in >or=5 of 6 patients.Fifteen patients (11 stage IV, 4 stage IIIB, 9 chemonaive, and 6 previously treated) received 85 courses. The most common toxicities were neutropenia, nausea/vomiting, malaise/fatigue, and peripheral neuropathy. No treatment-related hospitalizations, adrenal dysfunction, or episodes of sepsis occurred. The initial suramin dose resulted in the targeted concentrations of 10-20 microM at 48 h in 5 of the first 6 patients treated but also resulted in peak concentrations > 50 microM in all patients. Dividing the suramin dose to be administered in two doses, 24 h apart, yielded the target concentrations and avoided undesirable peak concentrations. Discernable antitumor activity occurred in 7 of 10 patients with measurable disease, including 2 with prior chemotherapy. The median time to tumor progression is 8.5 months (range, 3-27+ months) for 12 evaluable patients.Low-dose suramin does not increase the toxicity of paclitaxel/carboplatin combination. The suramin dose can be calculated based on clinical parameters. Because of the preliminary antitumor activity observed, efficacy studies in chemonaive and chemorefractory patients are under way." @default.
• W2145758314 created "2016-06-24" @default.
• W2145758314 creator A5004712121 @default.
• W2145758314 creator A5007739590 @default.
• W2145758314 creator A5015548619 @default.
• W2145758314 creator A5021892503 @default.
• W2145758314 creator A5024585813 @default.
• W2145758314 creator A5028329082 @default.
• W2145758314 creator A5050522883 @default.
• W2145758314 creator A5051619378 @default.
• W2145758314 creator A5055245295 @default.
• W2145758314 creator A5062080961 @default.
• W2145758314 creator A5063294295 @default.
• W2145758314 creator A5077645346 @default.
• W2145758314 creator A5085031128 @default.
• W2145758314 date "2003-08-15" @default.
• W2145758314 modified "2023-09-26" @default.
• W2145758314 title "Phase I study of low-dose suramin as a chemosensitizer in patients with advanced non-small cell lung cancer." @default.
• W2145758314 cites W1517390619 @default.
• W2145758314 cites W1546243656 @default.
• W2145758314 cites W1558301060 @default.
• W2145758314 cites W1567293882 @default.
• W2145758314 cites W1589936153 @default.
• W2145758314 cites W1779964374 @default.
• W2145758314 cites W1840478974 @default.
• W2145758314 cites W1842046266 @default.
• W2145758314 cites W1878893927 @default.
• W2145758314 cites W1897782182 @default.
• W2145758314 cites W1935885922 @default.
• W2145758314 cites W1967642037 @default.
• W2145758314 cites W1972580962 @default.
• W2145758314 cites W1976899949 @default.
• W2145758314 cites W1993945665 @default.
• W2145758314 cites W2000532353 @default.
• W2145758314 cites W2002756448 @default.
• W2145758314 cites W2005709557 @default.
• W2145758314 cites W2008633584 @default.
• W2145758314 cites W2008736019 @default.
• W2145758314 cites W2013135108 @default.
• W2145758314 cites W2021329274 @default.
• W2145758314 cites W2025021878 @default.
• W2145758314 cites W2025188342 @default.
• W2145758314 cites W2032619835 @default.
• W2145758314 cites W2035581814 @default.
• W2145758314 cites W2037139573 @default.
• W2145758314 cites W2039111821 @default.
• W2145758314 cites W2042700683 @default.
• W2145758314 cites W2049266437 @default.
• W2145758314 cites W2052874065 @default.
• W2145758314 cites W2056468963 @default.
• W2145758314 cites W2057147067 @default.
• W2145758314 cites W2058797642 @default.
• W2145758314 cites W2061674160 @default.
• W2145758314 cites W2067997630 @default.
• W2145758314 cites W2068893648 @default.
• W2145758314 cites W2071590971 @default.
• W2145758314 cites W2081439037 @default.
• W2145758314 cites W2084800358 @default.
• W2145758314 cites W2087884039 @default.
• W2145758314 cites W2094010374 @default.
• W2145758314 cites W2094255224 @default.
• W2145758314 cites W2099990230 @default.
• W2145758314 cites W2107466704 @default.
• W2145758314 cites W2116996913 @default.
• W2145758314 cites W2121676885 @default.
• W2145758314 cites W2122696814 @default.
• W2145758314 cites W2127916247 @default.
• W2145758314 cites W2139248078 @default.
• W2145758314 cites W2151232297 @default.
• W2145758314 cites W2155510257 @default.
• W2145758314 cites W2155689571 @default.
• W2145758314 cites W2163461071 @default.
• W2145758314 cites W2164735287 @default.
• W2145758314 cites W2169671930 @default.
• W2145758314 cites W2242063705 @default.
• W2145758314 cites W2268926393 @default.
• W2145758314 cites W2271214418 @default.
• W2145758314 cites W2277998802 @default.
• W2145758314 cites W2336297373 @default.
• W2145758314 cites W2347206875 @default.
• W2145758314 cites W2407515717 @default.
• W2145758314 cites W2412559323 @default.
• W2145758314 cites W2418332520 @default.
• W2145758314 cites W2467309903 @default.
• W2145758314 cites W2885877184 @default.
• W2145758314 cites W3145077989 @default.
• W2145758314 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/12960116" @default.
• W2145758314 hasPublicationYear "2003" @default.
• W2145758314 type Work @default.
• W2145758314 sameAs 2145758314 @default.
• W2145758314 citedByCount "12" @default.
• W2145758314 countsByYear W21457583142012 @default.
• W2145758314 countsByYear W21457583142014 @default.
• W2145758314 countsByYear W21457583142022 @default.
• W2145758314 countsByYear W21457583142023 @default.
• W2145758314 crossrefType "journal-article" @default.
• W2145758314 hasAuthorship W2145758314A5004712121 @default.
• W2145758314 hasAuthorship W2145758314A5007739590 @default.

• next